Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRUKER CORPBRKR · Entity 3609 | Chief Accounting Officer | August 15, 2026 | August 18, 2026 |
| PALVELLA THERAPEUTICS, INC.PIRS · Entity 4452 | Chief Financial Officer | February 24, 2023 | February 28, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRUKER CORP
Report date August 15, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,233 |
Reported balance
After 2026-08-15 transaction · row 1
1 source rowRow 1 · 2026-08-15 · Grant · Acquired 4,035 · Balance 7,233 F1: The Restricted Stock Units granted to the Reporting Person on August 15, 2026 (the "Original Grant Date") vest in equal installments on the first, second, third and fourth anniversaries of the Original Grant Date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Restricted Stock Units granted to the Reporting Person on August 15, 2026 (the "Original Grant Date") vest in equal installments on the first, second, third and fourth anniversaries of the Original Grant Date.
PALVELLA THERAPEUTICS, INC.
Report date February 24, 2023 · Filed February 28, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.39 · Expires 2033-02-24 | Direct | 249,080 |
Reported balance
After 2023-02-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-24 · Grant · Acquired 249,080 · Balance 249,080 F1: The option vests as to 25% of the option shares on February 24, 2024 and as to an additional 6.25% of the option shares at the end of each successive three-month period thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 25% of the option shares on February 24, 2024 and as to an additional 6.25% of the option shares at the end of each successive three-month period thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 15, 2026 Filed Aug 18, 2026 20:15 UTC | BRUKER CORP BRKR · Entity 3609 | GrantCommon Stock | 4,035 | $0.00 | $0.00 |
DisclosureSEC source: 0001787029-26-000004 · form4-08182026_040822.xml · nonDerivative · entry 1 Bures Thomas · CIK 0001787029 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,233 F1 · shares: The Restricted Stock Units granted to the Reporting Person on August 15, 2026 (the "Original Grant Date") vest in equal installments on the first, second, third and fourth anniversaries of the Original Grant Date. Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 21:15 UTC | BRUKER CORP BRKR · Entity 3609 | Tax withholdingCommon Stock | 274 | $36.51 | $10,003.74 |
DisclosureSEC source: 0001787029-26-000002 · form4-02182026_040205.xml · nonDerivative · entry 1 Bures Thomas · CIK 0001787029 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,198 F1 · shares: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person. Read SEC document |
| March 10, 2025 Filed Mar 11, 2025 20:11 UTC | BRUKER CORP BRKR · Entity 3609 | PurchaseCommon Stock | 500 | $47.40 | $23,697.50 |
DisclosureSEC source: 0001415889-25-007649 · form4-03112025_080323.xml · nonDerivative · entry 1 Bures Thomas · CIK 0001787029 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,472 Read SEC document |
| February 15, 2025 Filed Feb 19, 2025 21:39 UTC | BRUKER CORP BRKR · Entity 3609 | GrantCommon Stock | 2,972 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004656 · form4-02192025_090238.xml · nonDerivative · entry 1 Bures Thomas · CIK 0001787029 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,972 F1 · shares: The Restricted Stock Units granted to the Reporting Person on February 15, 2025 (the "Original Grant Date") vest in equal installments on the first, second, third and fourth anniversaries of the Original Grant Date. Read SEC document |
| February 24, 2023 Filed Feb 28, 2023 22:39 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Option (right to buy) · Derivative | 249,080 | $0.00 Strike: $1.39 | $0.00 |
DisclosureSEC source: 0001437749-23-004963 · rdgdoc.xml · derivative · entry 1 Bures Thomas · CIK 0001787029 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,080 Underlying: Common Stock · 249,080 shares Expires 2033-02-24 F1 · derivative.exercise_date: The option vests as to 25% of the option shares on February 24, 2024 and as to an additional 6.25% of the option shares at the end of each successive three-month period thereafter. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 21:46 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Options (Right to buy) · Derivative | 215,819 | $0.00 Strike: $3.03 | $0.00 |
DisclosureSEC source: 0001562180-22-001872 · primarydocument.xml · derivative · entry 1 Bures Thomas · CIK 0001787029 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,819 Underlying: Common Stock · 215,819 shares Expires 2032-02-22 F1 · derivative.exercise_date: The option vests as to 25% of the option shares on February 22, 2023 and as to an additional 6.25% of the option shares at the end of each successive three-month period thereafter. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 21:08 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Options (Right to buy) · Derivative | 150,000 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001562180-21-002058 · primarydocument.xml · derivative · entry 1 Bures Thomas · CIK 0001787029 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2031-03-04 F1 · derivative.exercise_date: The option vests as to 25% of the option shares on March 4, 2022 and as to an additional 6.25% of the option shares at the end of each successive three-month period thereafter. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 21:03 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001562180-20-001866 · primarydocument.xml · derivative · entry 1 Bures Thomas · CIK 0001787029 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2030-02-27 F1 · derivative.exercise_date: The option vests as to 25% of the option shares on February 27, 2021 and as to an additional 6.25% of the option shares at the end of each successive three-month period thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.